Filing Details
- Accession Number:
- 0000899243-18-013577
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-05-21 16:54:42
- Reporting Period:
- 2018-05-17
- Accepted Time:
- 2018-05-21 16:54:42
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1674416 | Crispr Therapeutics Ag | CRSP | Biological Products, (No Disgnostic Substances) (2836) | 473173478 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1682017 | Rodger Novak | C/O Crispr Therapeutics Ag Baarerstrasse 14 Zug V8 Ch-6300 V8 | President | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares | Acquisiton | 2018-05-17 | 35,240 | $1.81 | 1,183,247 | No | 4 | M | Direct | |
| Common Shares | Acquisiton | 2018-05-17 | 39,760 | $14.00 | 1,223,007 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2018-05-17 | 75,000 | $60.00 | 1,148,007 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2018-05-17 | 35,240 | $0.00 | 35,240 | $1.81 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2018-05-17 | 39,760 | $0.00 | 39,760 | $14.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 5,586 | 2025-09-10 | No | 4 | M | Direct | |
| 160,240 | 2016-10-18 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vest in 31equal monthly installments thereafter.
- This option was granted on October 18, 2016 with respect to 200,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016.
Billionaire Hedge Funds
